Adam M. Brufsky, MD, PhD

home / authors / adam-brufsky-md-phd

Articles

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

Adam M. Brufsky, MD, PhD;Xianchen Liu;Benjamin Li;Lynn McRoy;Connie Chen;Doris Makari;Rachel M. Layman;Hope S. Rugo, MD

August 20th 2024

11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above

Adam M. Brufsky, MD, PhD;Xianchen Liu;Benjamin Li;Lynn McRoy;Connie Chen;Rachel M. Layman;Hope S. Rugo, MD

April 28th 2023

7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

Adam M. Brufsky, MD, PhD;Hannah M. Linden, MD;Hope S. Rugo, MD;Joyce A. O’Shaughnessy;Robert H. Getzenberg;K. Gary Barnette;Domingo Rodriguez;Mitchell Steiner;Erica L. Mayer, MD, MPH

April 18th 2022

8 TiP Randomized, Multicenter, Phase 3 Study to Evaluate the Combination of Enobosarm and Abemaciclib Compared With Estrogen-Blocking Agent for the Second-Line Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Have Previously Received Palbociclib and an Estrogen-Blocking Agent Combination Therapy

Elgene Lim, MBBS, FRACP, PhD;Adam M. Brufsky, MD, PhD;Hope S. Rugo, MD;Charles L. Vogel, MD, FACP;Joyce A. O’Shaughnessy;Robert H. Getzenberg;K. Gary Barnette;Domingo Rodriguez;Mitchell Steiner;Hannah M. Linden, MD

April 18th 2022

Decision Making in Selecting Treatment in HER2+ BC

Adam M. Brufsky, MD, PhD;Neil M. Iyengar, MD;Vijayakrishna K. Gadi, MD, PhD;Sara A. Hurvitz, MD

May 18th 2021

Experts provide insights on clinical decision-making in the setting of patient with HER2+ breast cancer.

Management Approaches for Patients with HER2+ BC at Risk for Brain Metastases

Adam M. Brufsky, MD, PhD;Neil M. Iyengar, MD;Vijayakrishna K. Gadi, MD, PhD;Sara A. Hurvitz, MD

May 11th 2021

An expert panel of breast oncologists discusses factors they consider when deciding whether to screen a patient with HER2+ breast cancer for brain metastases.

Patient Case: A 37-Year-Old Woman With HER2+/HR- Breast Cancer

Adam M. Brufsky, MD, PhD;Neil M. Iyengar, MD;Vijayakrishna K. Gadi, MD, PhD;Sara A. Hurvitz, MD

May 11th 2021

Adam Brufsky, MD, PhD, presents the case of a 37-year-old woman with HER2+/HR- metastatic breast cancer and polls the audience about screening for brain metastases.

$Relapsed/Refractory HER2+ Metastatic Breast Cancer$

Relapsed/Refractory HER2+ Metastatic Breast Cancer

Adam M. Brufsky, MD, PhD;Neil M. Iyengar, MD;Sara A. Hurvitz, MD;VK Gadi, MD, PhD

February 15th 2021

Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.

A Closer Look at HER2-Targeted Therapies

Adam M. Brufsky, MD, PhD

October 31st 2018

Dr. Adam Brufsky speaks with Cancer Network about the evolution and future of HER2-targeted therapy.

Bisphosphonates in Breast Cancer: A Triple Winner?

Aju Mathew, MD, MPhil;Adam M. Brufsky, MD, PhD

January 15th 2015

We know that bisphosphonates prevent or delay skeletal-related events in breast cancer metastatic to bone, prevent or treat bone loss in patients receiving adjuvant aromatase inhibitor therapy, and decrease bone recurrences and breast cancer–related deaths when used in the adjuvant setting in postmenopausal women with early-stage breast cancer.